Exploratory analyses of prognostic factors
neutropenia
LIVER METASTASIS, METASTASIS, NEUTROPENIA
Baseline characteristics associated with neutropenia and PFS were explored in the analysis of potential prognostic factors. In total, 836 patients with complete data on prognostic factors were retained in the final model of prognostic factors for neutropenia or severe neutropenia, and 808 patients were retained in the final model to investigate potential prognostic factors for PFS.Identified prognostic factors favouring the occurrence of neutropenia during treatment with FTD/TPI were time since diagnosis of the first metastasis of ≥18 months, baseline haemoglobin ≥110 g/l, NLR < 3, baseline AST grade 0, baseline albumin ≥35 g/l, previous lines of treatment > 2, and baseline white blood cell count < 10 × 10Identified prognostic factors associated with longer PFS were time since diagnosis of the first metastasis of ≥18 months, < 3 metastatic sites, ECOG-PS 0 at baseline, absence of liver metastasis, no previous treatment with regorafenib, baseline NLR < 5, baseline alkaline phosphatase grade 0, baseline AST grade 0, baseline albumin ≥35 g/l, and baseline white blood cell count < 10 × 10Prognostic factors for PFS (Median PFS was longer in patients experiencing neutropenia during FTD/TPI treatment compared with those having no neutropenia (Supplementary Fig. 